Table 1. Characteristics of included studies assessing APLA and the risk of RVO.

Author	Publication year	Country	All subjects	Control source	Age (year)	Antibody type	Diagnostic methods
Maaroufi RM et al	2004	Tunisia.	113	Healthy control	11–63	IgG, IgM	Fundus fluorescein
Risse F et al	2014	Germany	179	Healthy control	62.9	NA	Clinical History
Cobo-Soriano R et al	1999	Spain	80	No RVO	55	IgG, IgM	Recently diagnosed
Adamczuk YP	2002	Argentina	141	Healthy control	49	IgG, IgM	Clinical History
Van Cott E	2004	USA	60	No RVO	57	IgG, IgM	Clinical History
Atchaneeyasakul LO	2005	Thailand	131	Healthy control	54	IgG	Clinical History
Abu el-Asrar AM	1996	Saudi Arabia	87	Healthy control	38.7	IgG, IgM	Fundus fluorescein
Glacet-Bernard A	1994	France	106	No RVO	47	IgG, IgM	Clinical History
Glueck CJ	2012	USA	237	Healthy control	55	IgG, IgM	Clinical History
Abu El-Asrar AM	1998	Saudi Arabia	131	Healthy control	51	IgG, IgM	Recently diagnosed
Marcucci R	2001	Italy	200	Healthy control	57.5	IgG, IgM	Clinical History